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Abstract 
Background: Cancer and sepsis comorbidity is a major public health problem in 
most parts of the world including Zimbabwe. The microbial aetiologies of sepsis and 
their antibiograms vary with time and locations. Knowledge on local microbial 
aetiologies of sepsis and their susceptibility patterns is critical in guiding empirical 
antimicrobial treatment choices.  
Methods: This was a descriptive cross-sectional study which determined the 
microbial aetiologies of sepsis from blood cultures of paediatric and adult cancer 
patients obtained between July 2016 and June 2017. The TDR-X120 blood culture 
system and TDR 300B auto identification machine were used for incubation of blood 
culture bottles and identification plus antimicrobial susceptibility testing, respectively. 
Results: A total of 142 participants were enrolled; 50 (35.2%) had a positive blood 
culture, with 56.0% Gram positive, 42.0% Gram-negative bacteria and 2.0% yeast 
isolated. Common species isolated included coagulase negative Staphylococcus 
spp. (CoNS) (22.0%), E. coli (16.0%), K. pneumoniae (14.0%), E. faecalis (14.0%) 
and S. aureus (8.0%). Gram-negative isolates exhibited high resistance to 
gentamicin (61.9%) and ceftriaxone (71.4%) which are the empiric antimicrobial 
agents used in our setting. Amikacin and meropenem showed 85.7% and 95.2% 
activity respectively against all Gram-negative isolates, whilst vancomycin and 
linezolid were effective against 96.2% and 100.0% of all Gram-positive isolates 
respectively. We isolated 10 (66.7%) extended spectrum β-lactamase (ESBL) 
amongst the E. coli and K. pneumoniae isolates. Ten (66.7%) of the Staphylococcus 
spp. were methicillin resistant. 
Conclusions: CoNS, E. coli, K. pneumoniae, E. faecalis and S. aureus were the 
major microbial drivers of sepsis amongst cancer patients in Zimbabwe. Most 
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isolates were found to be resistant to commonly used empirical antibiotics, with 
isolates exhibiting high levels of ESBL and methicillin resistance carriage. A 
nationwide survey on microbial aetiologies of sepsis and their susceptibility patterns 
would assist in the guidance of effective sepsis empiric antimicrobial treatment 
among patients with cancer. 
Keywords 
Sepsis; cancer; aetiology; antimicrobial resistance; ESBL 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  
 
 
Background 
Despite the major advances in the care of patients with cancer over the past few 
decades and the resultant improvement in survival, complications during the course 
of disease arise that are associated with significant morbidity and mortality (1). 
Cancer is one of the leading risk factors of developing sepsis, with cancer patients 
having a 10-fold relative risk compared to non-cancer patients (2). In addition to 
being a leading cause of hospitalisation in this population, sepsis represents a 
common pathway of mortality among cancer patients (3). The comorbidity of sepsis 
and cancer poses serious complications with very poor prognosis with a case fatality 
ratio of greater than 50% in the Americas (4). Sepsis as a syndrome can result from 
healthcare–associated or community–acquired infection by organisms and these 
organisms can develop resistance to commonly prescribed antimicrobial agents (5). 
Without proper determination of antimicrobial susceptibility patterns of these 
organisms, treatment may prove to be difficult, leading to other complications like 
organ failure, shock and death (6). 
Among cancer patients with sepsis the organisms commonly isolated are bacterial or 
fungal pathogens, with the predominant pathogens being Staphylococcus aureus, 
Pseudomonas species, Escherichia coli, and Candida species (1,7). Laboratory 
investigations in sepsis include measurement of inflammatory markers, organ 
function tests and identification of infectious source through blood culture plus any 
culture specimens to identify source of infection (5,8). In Zimbabwe, sepsis diagnosis 
is primarily clinically based and confirmation of infection with blood cultures is not 
always adhered to particularly in the public health institutions. 
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According to guidelines in Zimbabwe, sepsis is empirically treated with gentamicin 
and either benzylpenicillin or cloxacillin with ceftriaxone and chloramphenicol being 
used as empiric antibiotics when involvement with the central nervous system is 
suspected (9). Evidence from literature demonstrates variations in aetiological 
agents of sepsis in different geographical settings, thus microbial and antimicrobial 
profiling should be country/region specific (6,7,10,11). With the rise of antimicrobial 
resistance among clinical isolates, it is imperative to profile the causative pathogens 
of sepsis and their antimicrobial patterns. This could aid in reducing patient hospital 
costs, sepsis related complications and deaths.  
To date, the burden of sepsis in cancer patients and or their causative pathogens 
remain sparse in Zimbabwe and Africa at large, despite the growing burden of 
cancer. Thus, this study aimed to ascertain the microbial agents of sepsis and their 
antimicrobial susceptibility patterns among hospitalised paediatric and adult patients 
with cancer in Zimbabwe.  
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Methods 
Study design and study population  
Between July 2016 and June 2017, we performed a prospective descriptive cross-
sectional study among hospitalised paediatric and adult haematology/oncology 
patients at a single centre, Parirenyatwa Group of Hospitals. It is the biggest and 
major referral centre for patients with cancer in Zimbabwe and is located in the 
capital city, Harare. The target population were paediatric patients at least 1-year of 
age and adult patients who had a diagnosis of cancer, presenting with signs of 
sepsis. The participants included had to have the following; suspected infection with 
at least fever (<36⁰C or >380C), heart rate (>90 bpm) and white cell count (<4.0 x 109 
or >12.0 x 109/L). Clinical assessment of sepsis was done using the quick Sequential 
Organ Failure (qSOFA) score which includes (1) respirations >22 breaths/minute, (2) 
altered mentation, (3) systolic blood pressure <100 mmHg, with two or more 
considered ‘high’ risk (12). The qSOFA score ranges from 0 to 3, with each criterion 
being worth one point. When respiration rate, altered mentation, or systolic blood 
pressure data was not available, the corresponding criterion was set to be worth zero 
point. For the 48% of patients (68/142) for whom clinical data was complete, the 
qSOFA score (12), including (1) creatinine >110 µMol/L, (2) platelets <150 x 103/µL, 
and (3) total bilirubin >20 µMol/L was also calculated. 
Sample collection and analysis 
At least two peripheral vein blood samples were consecutively drawn aseptically for 
blood cultures from paediatrics (3ml each) and adult (8ml each) per participant. The 
TDR Resin Aerobic or TDR Resin Peds (Hunan Changsha Tiandiren Bio-Tech Co., 
Ltd., Changsha, China) blood culture bottles, which support growth of both aerobic 
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bacteria and mycotic yeasts, were used for sample collection from participants. The 
collected blood culture samples were processed and cultured using standard 
microbiology hospital protocols. Briefly, TDR Resin Aerobic or TDR Resin Peds 
(Hunan Changsha Tiandiren Bio-Tech Co., Ltd., Changsha, China) blood culture 
bottles, from the participants were incubated at 37oC in an automated microbial 
detection blood culture system TDR-X120 (Hunan Changsha Tiandiren Bio-Tech 
Co., Ltd., Changsha, China). Blood cultures read as positive by the analyser were 
immediately retrieved, Gram stained and sub-cultured on Blood agar, MacConkey 
agar, Chocolate agar and Sabouraud dextrose agar supplemented with 
chloramphenicol (0.5g/l) (all Mast Group Ltd., Merseyside, UK) plates for 48-hours. 
The blood culture system has an incubation period of up to 5-days, after which it 
reports a blood culture specimen as negative for growth. All negative blood cultures, 
as read by the machine, were also Gram stained and sub-cultured similarly as the 
positive ones to confirm the negative result. We only considered a patient to be 
infected, when at least two of the blood cultures had been positive. A single positive 
blood culture result was interpreted as possible contamination. 
Identification and antimicrobial susceptibility testing of isolates 
Isolates grown from culture plates were initially identified as lactose fermenting 
coliform, non-lactose fermenting coliform, oxidase positive (non-fermenter) Gram-
negative rods, Staphylococcus, Streptococcus species or yeasts based on colony 
morphology. These were further speciated by means of various biochemical tests 
and antimicrobial susceptibility test (AST) using standard methods on the Mindray 
TDR 300B (Hunan Changsha Tiandiren Bio-Tech Co., Ltd., Changsha, China) 
following the manufacturer’s manual. Probabilities were calculated from these results 
using the Bifido-Matrix method to identify the most possible organism. Antimicrobial 
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susceptibility testing plates were read on the TDR 300B based on turbidity and 
interpretations were made using breakpoints stipulated in the Clinical and Laboratory 
Standards Institute (CLSI) 2017 guidelines (13). Isolates found to be multidrug 
resistant were tested for Extended Spectrum β-Lactamase production, methicillin 
resistance and carbapenemase production as described in the CLSI standard (13). 
Pseudomonas aeruginosa ATCC® 27853, E. coli ATCC® 25922 and S. aureus 
ATCC® 25923 strains were used for quality control (QC) during identification and 
AST on the Mindray TDR 300B machine. 
Statistical analysis 
Characteristics of the study participants were analysed using descriptive statistics 
with results expressed as frequencies and percentages. Aetiological profiles were 
described for the overall sample using percentages and their distribution by cancer 
types. All data analysis was performed using Stata software v13 (StataCorp). 
Observations with missing values were coded as missing and reported as such. 
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Results 
Demographic characteristics of the population  
A total of 142 consecutive hospitalised cancer participants with clinical diagnosis of 
sepsis were recruited into the study, with females 76 (53.5%) and paediatric patients 
86 (60.6%) being the majority. The age ranged between 1 – 85 years, with an overall 
median age 10 (interquartile range [IQR]: 5 – 24) years and a median in-patient 
hospital stay of 7 (IQR: 4 – 15) days before diagnosis of sepsis was suspected. One 
hundred and ten (77.5%) participants had haematological neoplasms which 
comprised mostly of leukaemias and lymphomas whilst 32 (22.5%) had solid 
tumours such as Wilms tumour, rhabdomyosarcoma and hepatocellular carcinoma. 
Neutropenia, one of the major sepsis risk factors, was assessed from the patients’ 
absolute neutrophil counts. The absolute neutrophil count of patients on blood 
culture sample collection ranged between 20 – 102 700 cells/µl. Neutropenia (< 1000 
cells/µl) as previously defined in other studies (7,14) was observed in 43 (39.1%) of 
the participants with haematological neoplasm and one participant with a solid 
tumour giving a total of 44 (31.0%) neutropenic patients. There was a strong 
association between having a haematological neoplasm and being neutropenic 
(Odds Ratio, 19.9; 95%CI 3.0 – 829.2; p-<0.001). Participants’ demographic 
characteristics are summarised in Table 1. 
Blood cultures and pathogens isolated    
Of the 142 participants, fifty (35.2%) had positive blood cultures. Thirty-nine of the 
110 patients with haematological malignancies had positive blood cultures with a 
positive isolation rate of 35.5% contributing 78% of the total number of isolates. 
Gram-positive bacterial pathogens were the predominant 28 (56.0%) of the 
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causative agents of sepsis in this population with coagulase negative 
Staphylococcus spp. (CoNS) being the majority contributing 22.0% of the pathogens 
isolated. E. coli was the second most abundant 8 (16.0%) species isolated. Candida 
albicans was the only fungal pathogen isolated from one participant with sepsis in 
this study. Table 2 summarises our findings. 
Exposure to antimicrobials and antimicrobial susceptibility profiles 
One hundred and twenty-nine 129(90.8%) of our participants were exposed to at 
least one antimicrobial agent at least 48-hours prior to blood culture collection. The 
most commonly prescribed antibiotic was ceftriaxone 100/129 (77.5%) followed by 
gentamicin 75/129 (58.1%) and ciprofloxacin 33 (25.6%). Twenty-seven (20.9%) 
participants were on fluconazole therapy. At least 3 antibiotics had been 
administered to 58.0% of the participants prior to blood culture collection.  
After performing AST on the isolates, Staphylococci spp. had the highest resistance 
to penicillin 14 (93.7%), with methicillin resistance observed in 10 (66.7%) of the 
Staphylococci isolates. Based on CLSI 2017 guideline, the same results can be 
applied to cloxacillin, augmentin and cefazolin. However, all the isolates were fully 
susceptible to vancomycin and linezolid. 
Among the Gram-negative bacterial isolates, antibiotics such as levofloxacin 
(52.4%), cefepime (61.9%), cefoxitin (66.7%), piperacillin-tazobactam (71.9%), 
amikacin (85.7%) and meropenem (95.2%) exhibited moderate to high potency 
against all Gram-negative isolates. Ampicillin and trimethoprim-sulfamethoxazole 
were least effective with only 4.8% of the isolates being sensitive. High level of 
resistance was observed among K. pneumoniae followed by E. coli isolates. Among 
K. pneumoniae isolates, resistance was observed in ampicillin (100%), trimethoprim-
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sulfamethoxazole (85.7%) and third generation cephalosporins (71.4%) respectively. 
Resistance to gentamicin, one of the first line empiric antimicrobial in our setting, 
was 57.1% among K. pneumoniae isolates. Against third generation cephalosporins 
that is ceftriaxone, an empiric antimicrobial in the local Essential Medicines List and 
Standard Treatment Guidelines for Zimbabwe (EDLIZ), and ceftazidime, resistance 
was observed in 71.4% of these isolates. However, isolates were fully sensitive to 
amikacin and meropenem and moderately sensitive to cefoxitin (85.7%). E. coli 
isolates were also fully susceptible to meropenem and amikacin while 75.0% of the 
isolates were resistant to ceftriaxone, ceftazidime, gentamicin, ciprofloxacin and 
levofloxacin (see table 4). Trimethoprim-sulfamethoxazole and ampicillin displayed 
the least activity against E. coli isolates with sensitivities of 0.0% and 12.5% 
respectively. Other isolates were few to make inferences as they were only a single 
isolate of each species. These included Serratia odorifera, Acinetobacter species, 
Salmonella enteritidis, Enterobacter intermedium and Hafnia alvei. Of note, the S. 
odorifera was only sensitive to levofloxacin and resistant to meropenem and 
ertapenem. Overall, the proportions of isolates resistant to empiric antimicrobial 
agents in Zimbabwe (gentamicin and ceftriaxone) among Enterobacteria species 
were 61.9% and 71.4 respectively. 
When we investigated the Enterococcus species, the isolates were fully susceptible 
to linezolid and vancomycin, while they showed high resistance to tetracycline 2 
(20.0%) and ciprofloxacin 4 (40.0%). E. gallinarum was resistant to the majority of 
drugs with the two isolates being sensitive to vancomycin and linezolid. 
Streptococcus species on the other hand were all resistant (66.7%) to tetracycline, 
ampicillin and penicillin. One Streptococcus species, which was identified as 
Streptococcus bovis, showed resistance to vancomycin. Overall, 69.2% isolates of 
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Enterococcus and Streptococcus species were susceptible to the empiric 
antimicrobial agents, high dose gentamicin and penicillin. 
Finally, a single isolate of C. albicans was the only fungal pathogen isolated from the 
blood cultures. It proved to be resistant to terbinafine, itraconazole and fluconazole.  
However, the isolate was sensitive to other antifungals such as micafungin, 
caspofungin, voriconazole, ketoconazole, miconazole, amphotericin B and 
flucytosine. Tables 3 to 5 summarises the antimicrobial susceptibility patterns of all 
the isolates. 
Incidence of ESBL production among E. coli and K. pneumoniae isolates 
Fifteen isolates of both E. coli and K. pneumoniae obtained in this study were 
screened for ESBL enzyme production and 10 (66.7%) were phenotypically 
confirmed to be ESBL producers.  E. coli isolates were the main ESBL producers 
with 6/8 (75.0%). Four (57.1%) of the total K. pneumoniae isolates were also 
confirmed ESBL producers. 
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Discussion 
Sepsis is a serious life-threatening condition that commonly manifests itself in the 
cancer patients. Although there are studies that have been conducted in Africa on 
cancer patients presenting with sepsis (10,15), limited data regarding the profiles of 
the organisms implicated and antibiotic susceptibility data exist. In this study we 
report the isolation rate of bacterial and fungal pathogen from blood cultures of 
cancer patients (both adults and paediatric) presenting with sepsis, as well as the 
antimicrobial profiles of commonly used antibiotics in our setting. We also 
demonstrate that there is a high level of resistance among pathogen causing sepsis 
in our setting. 
Patients with haematological malignancies were the majority (77.5%) and this could 
be due to neutropenia secondary to chemotherapy which further exposes them to 
infections. The overall proportion of the patients who were neutropenic was 31.0% 
which is similar to the 30.0% reported in the USA (7). Patients with haematological 
malignancies showed a significantly higher proportion of neutropenia compared to 
those with solid cancers, a finding similar to the Chinese and European populations 
(14,17). 
The majority (90.8%) of the study participants were on at least one antimicrobial 
agent at least 48 hours prior to blood culture collection and this was as a 
consequence of their immunosuppression being caused by the cancer. However, it 
was also observed that 82 (57.7%) were on a cocktail of 3 to 6 broad spectrum 
antimicrobial agents contrary to the standard empirical treatment of sepsis stipulated 
in the local EDLIZ (9). Ceftriaxone and gentamicin were the major empirical 
antibiotics used despite the recommendations that ceftriaxone should only be used 
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as second line (9). Use of ceftriaxone and other antimicrobials as first line empiric 
antimicrobial treatment could be due to limited knowledge on the implications such 
as antimicrobial resistance and presumed resistance to prescribed empiric 
treatment. 
Our microbial pathogen isolation rate was 35.2% which is slightly higher than the 
average of 20 and 30% range in most studies (2,4,8). Other studies from high 
income countries have, on the contrary, reported lower prevalence of sepsis among 
patients with cancer including studies in Oman (5.0%) and Europe (17%) (14,18). 
Among the isolates identified, Gram-positive to Gram-negative percentage ratio was 
57:43 which was comparable with the median ratio of 60:40 (range 85:15 to 26:76) 
obtained in Europe (16,19). This reflects a similarity in the distribution of organisms 
despite geographical differences although minor difference can be encountered, like 
a study in Sudan where the ratio was 83%:17% (10). Most of the isolates (78.0%) 
came from patients with haematological malignancies, a finding comparable to other 
earlier studies (4,14). The major aetiological agents of sepsis obtained from patients 
with haematological cancers were CoNS, E. coli, E. faecalis and K. pneumoniae. 
Similarly, other studies from Europe have reported the same organisms as the 
causative agents of sepsis but with some minor variations in proportions (14,16). 
Most studies had not stratified aetiological agents with cancer type but a study in 
Europe with the same stratification showed similar aetiological agents between the 
two major cancer groups (14). 
Amikacin and meropenem were the most potent drugs against Gram-negative 
isolates with more than 80.0% of the isolates being sensitive, similar to findings from 
a study in the USA (7). Conversely, more than 60.0% of the isolates were resistant to 
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third generation cephalosporins, in contrast with the USA and an earlier study in 
Zimbabwe where 80-100% were sensitive (7,20). This difference could be due to the 
wide availability and uncontrolled use of ceftriaxone as first line treatment, as was 
found in this study. As also shown in this and other studies (16,21–23), the increase 
in the emergence of ESBL producing isolates has also led to this high level of 
resistance to the third generation cephalosporins. Gentamicin, the most commonly 
used empirical aminoglycoside, also had a low activity against these Gram-negative 
isolates as >60.0% of the isolates were resistant. Resistance to third generation 
cephalosporins and gentamicin has been reported in earlier studies to be rising in 
low-income countries (22,24). Such resistance to the empiric antimicrobial agents 
poses a challenge in the management of sepsis among this population as it limits 
treatment options hence the need to review empiric treatment options. Cefoxitin and 
piperacillin-tazobactum were effective against 66.7% and 71.4% of all the Gram-
negative isolates. However, more than 90.0% of the isolates were resistant to 
trimethoprim-sulfamethoxazole and ampicillin, a finding similar to most studies 
worldwide (17,20,24). The resistance to trimethoprim-sulfamethoxazole has been 
attributed to overuse of the drug as prophylaxis against Pneumocystis jirovecii 
pneumonia in HIV endemic regions such as Zimbabwe. Notably, there was one S. 
odorifera isolate that was resistant to meropenem and ertapenem. This is surprising 
as carbapenem resistance Enterobacteriaceae has not been reported before in 
Zimbabwe. However, the isolate was not confirmed with polymerase chain reaction 
for carbapenemase resistance gene carriage. Nevertheless, this could be a possible 
emergence of carbapenemase resistance since carbapenems are being employed 
routinely for management of patients in the institution under study. 
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Expectedly, due to their limited use locally, minocycline, chloramphenicol, linezolid 
and vancomycin showed to be effective against more than 80.0% of the 
Staphylococcus isolates. A moderately high activity was displayed by gentamicin, 
clindamycin and erythromycin. These results were partly in agreement with findings 
from Ghana and India (24,25). Conversely, there was high rate of methicillin 
resistance which impliedly apply to cloxacillin, one of the EDLIZ prescribed empiric 
antimicrobial agent. The low activity observed in penicillin was previously reported in 
Ghana, India and Zimbabwe (20,24,25). Enterococcus and Streptococcus species in 
our study were highly sensitive to fosfomycin, vancomycin and linezolid with the 
latter being the most effective (isolates were 100.0% sensitive) antibiotic. Contrary to 
findings in India where they found 50% of Enterococcus species to be resistant to 
vancomycin, all our isolates were sensitive to vancomycin (26). These isolates also 
displayed a moderate sensitivity to gentamicin, ampicillin and penicillin. Surprisingly, 
one isolate of Streptococcus bovis was resistant to vancomycin, a finding that has 
not been reported before in Zimbabwe. However, vancomycin resistance amongst 
Streptococcus bovis has been reported before in some parts of the world (27).  
Some isolates phenotypically showed multidrug resistance capabilities. Our 
methicillin resistance carriage was comparable to USA isolates where MRSA was 
50.0% in our current study versus 41.0% in USA while that of methicillin resistant 
CoNS was 75.0% versus 72.0% respectively (7). In Ghana, a low proportion of 
MRSA (5.8%) was reported in contrast to our findings (24). This high-level methicillin 
resistance limits the choices of antimicrobial treatment since it also implies that these 
isolates will also be clinically resistant to most if not all commonly used beta-lactam 
antibiotics. We also found a high proportion of ESBL producers among E. coli and K. 
pneumoniae isolates and this was in agreement with some studies around the world 
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(16,21,22,28). However, of note was a higher proportion of ESBL producing E. coli 
(75.0%) than K. pneumoniae (57.1%), a different finding from most reports in other 
parts of the world where ESBL production is predominantly found in K. pneumoniae 
isolates (21,22). 
Conclusion 
In summary, sepsis remains a leading cause of morbidity and mortality among 
patients with cancer; with the major aetiological agents being CoNS, E. coli, K. 
pneumoniae, E. faecalis and S. aureus. Similar aetiological pathogens were present 
in both haematological and solid cancers in the Zimbabwean population. Most of the 
microbial aetiological agents of sepsis showed high levels of resistance to commonly 
used antimicrobial drugs as well as to those prescribed as local empiric treatment. 
Resistance to gentamicin, penicillin and third generation cephalosporins is a major 
cause for concern as these are the major empirical antibiotics in resource limited 
settings. Apart from vancomycin, linezolid was shown to be another better option to 
be considered in the treatment of serious and non-responsive Gram-positive 
infections while amikacin and meropenem can also be considered in Gram-negative 
infections. The emergence of multidrug resistance mechanisms like ESBL, 
carbapenemase carriage and methicillin resistance among isolates is disturbing and 
this demonstrates the need for active surveillance to reduce their transmission with a 
goal to mitigate mortality and morbidity among patients. 
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Table 1: Study population demographic characteristics 
Characteristic  Total Haematological neoplasm Solid tumour 
Female n (%) 76 (53.5) 58 (76.3) 18 (23.7) 
Age  median (IQR) years - 15 (4 – 34) 6 (5 – 10) 
Paediatric (oncology ward) n (%) 86 55 (64.0) 31 (36.0) 
Adults (oncology ward) n (%) 1 - 1 (100.0) 
Adult (haematology ward) n (%) 55 55 (100.0) - 
Hospital stay median (IQR) days 7.0 (4 – 15) 7.0 (4 – 15) 7.5 (3 – 13) 
Neutropenia n (%) 44 (31.0) 42 (39.1) 1 (3.1) 
n, number
Table of results Click here to access/download;Table;Tables Frank Chinowaita, Sepsis in cancer
patients.doc
Table 2: Distribution of sepsis causing pathogens in participants with cancer 
 
Causative pathogen 
Number of isolates (n)  
Total (%) Haematological 
neoplasm 
Solid tumour 
Children Adults Children adults 
Gram-negative bacteria (n=21) 
Escherichia coli 4 2 2 - 8 (16.0) 
Klebsiella pneumoniae 2 3 2 - 7 (14.0) 
Enterobacter intermedium 1 - -  1 (2.0) 
Serratia odorifera - 1 - - 1 (2.0) 
Acinetobacter species 1 - - - 1 (2.0) 
Pseudomonas aeruginosa 1 - - - 1 (2.0) 
Salmonella enteritidis - 1 - - 1 (2.0) 
Hafnia alvei - - 1 - 1 (2.0) 
Gram positive bacteria (n=28) 
 CoNS 3 6 2 - 11 (22.0) 
Staphylococcus aureus 2 1 - 1 4 (8.0) 
Enterococcus faecalis 1 5 1 - 7 (14.0) 
Enterococcus gallinarum 2 - - - 2 (4.0) 
Enterococcus faecium 1 - - - 1 (2.0) 
Streptococcus species 0 1 2 - 3 (6.0) 
Fungi (n=1) 
Candida albicans 1 - - - 1 (2.0) 
n, number 
 
Table 3: Distribution of drug susceptible Staphylococcus species 
 
Notes: VA, vancomycin; LIN, linezolid; ERY, erythromycin; CD, clindamycin; TET, tetracycline; MINO, minocycline; RIF, rifampicin; 
CHL, chloramphenicol; CIP, ciprofloxacin; GM, gentamicin; PEN, penicillin; COT, trimethoprim-sulfamethoxazole; N, number; (0), 
zero susceptible isolates    
 
 
 
 
 
 
 
Bacterial species 
isolates 
N VA LIN ERY CD TET MINO RIF GM CIP PEN COT 
S. aureus 4 4 4 2 3 3 3 3 3 2 0 2 
CoNS 11 11 11 7 7 5 9 8 6 5 1 6 
Total sensitive n (%) 15(100) 15(100) 15(100) 9(60.0) 10(66.7) 8(53.3) 12(80.0) 11(73.3) 9(60.0) 7(46.7) 1(6.7) 8(53.3) 
Table 4: Distribution of antimicrobial susceptibility patterns for gram negative isolates 
 
 
 
 
 
 
 
 
 
 
 
Notes: AMP, ampicillin; PTZ, piperacillin-tazobactam; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; CEF, cefepime; 
FOX, cefoxitin; GM, gentamicin; AK, amikacin; CIP, ciprofloxacin; LEV, levofloxacin; COT, trimethoprim-sulfamethoxazole; MEM, 
meropenem; N, number; (-), not tested; (0), zero sensitive isolates  
Bacterial 
isolates 
N AMP PTZ CXM CRO CAZ CEF FOX GM AK CIP LEV MEM COT 
E. coli 8 1 7 2 2 2 4 7 2 8 2 2 8 0 
K. pneumoniae 7 0 4 2 2 2 4 6 3 7 3 4 7 1 
E. intermedium 1 0 1 0 0 0 1 0 1 0 1 1 1 0 
S. odorifera 1 0 0 0 0 0 0 0 0 0 0 1 0 0 
S. enteritidis 1 0 1 0 1 1 1 0 0 0 1 1 1 0 
Acinetobacter sp. 1 0 0 0 1 1 1 0 0 1 0 0 1 0 
P. aeruginosa 1 - 1 - 0 1 1 - 1 1 1 1 1 0 
H. alvei 1 0 1 0 0 0 1 1 1 1 1 1 1 0 
Total n (%) 21 
(100) 
1(4.8) 15(71.4) 4(19.0) 6(28.6) 7(33.3) 13(61.9) 14(66.7) 8(38.1) 18(85.7) 9(42.9) 11(52.4) 20(95.2) 1(4.8) 
Table 5: Antimicrobial susceptibility patterns for Streptococcus and Enterococcus species 
Bacterial 
isolates 
N AMP PEN VA LINE FOSF GM TET CIP LEV GATI 
E. faecalis 7 7 7 7 7 7 6 2 4 4 4 
E. gallinarum 2 0 0 2 2 1 0 0 0 0 0 
E. faecium 1 1 1 1 1 1 1 0 0 1 1 
Streptococcus 
sp. 
3 1 1 2 3 2 2 1 2 2 2 
Total N (%) 13(100) 9(69.2) 9(69.2) 12(92.3) 13(100) 11(84.6) 9(69.2) 3(23.1) 6(46.2) 7(53.8) 7(53.8) 
Notes: AMP, ampicillin; PEN, penicillin; VA, vancomycin; LINE, linezolid; FOSF, fosfomycin; GM, gentamicin; TET, tetracycline; 
LEV, levofloxacin; CIP, ciprofloxacin; GATI, gatifloxacin; N, number; (0), zero sensitive isolates 
